Literature DB >> 21448143

Telomerase and the endocrine system.

Furio Pacini1, Silvia Cantara, Marco Capezzone, Stefania Marchisotta.   

Abstract

Telomeres are nucleoprotein complexes located at the ends of chromosomes that have a critical role in the maintenance of chromosomal integrity. This involvement is based on complex secondary and tertiary structures that rely on DNA-DNA, DNA-protein and protein-protein interactions. De novo synthesis and maintenance of telomere repeats is controlled by telomerase, a specialized complex that consists of a telomerase RNA component and a protein component--telomerase reverse transcriptase. When telomerase is silent (its default state in differentiated somatic cells), chromosomes shorten with every cell division, thus limiting the lifespan of the cells (the process of senescence) and preventing unlimited cell proliferation, which might eventually lead to the development of cancer. During this process, occasionally, a cell can activate telomerase, which stabilizes short telomeres and enables immortalization-a process essential for malignant transformation. Thus, although telomere erosion is a barrier to malignant progression, paradoxically, in certain circumstances it might also trigger tumorigenesis. A number of studies have demonstrated unequivocally that reactivation of telomerase in the presence of short telomeres is one of the most common features of human cancers, including those of the endocrine system.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21448143     DOI: 10.1038/nrendo.2011.52

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN: 1759-5029            Impact factor:   43.330


  120 in total

1.  Crystal structure of the essential N-terminal domain of telomerase reverse transcriptase.

Authors:  Steven A Jacobs; Elaine R Podell; Thomas R Cech
Journal:  Nat Struct Mol Biol       Date:  2006-02-05       Impact factor: 15.369

2.  Telomerase activity in human germline and embryonic tissues and cells.

Authors:  W E Wright; M A Piatyszek; W E Rainey; W Byrd; J W Shay
Journal:  Dev Genet       Date:  1996

3.  Telomerase activity in ovarian tumors.

Authors:  J Murakami; N Nagai; K Ohama; H Tahara; T Ide
Journal:  Cancer       Date:  1997-09-15       Impact factor: 6.860

4.  Origin of concatemeric T7 DNA.

Authors:  J D Watson
Journal:  Nat New Biol       Date:  1972-10-18

5.  A tandemly repeated sequence at the termini of the extrachromosomal ribosomal RNA genes in Tetrahymena.

Authors:  E H Blackburn; J G Gall
Journal:  J Mol Biol       Date:  1978-03-25       Impact factor: 5.469

6.  Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.

Authors:  S K Nair; A Heiser; D Boczkowski; A Majumdar; M Naoe; J S Lebkowski; J Vieweg; E Gilboa
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

7.  Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma.

Authors:  Carsten Boltze; Jochen Mundschenk; Nicole Unger; Regine Schneider-Stock; Brigitte Peters; Christian Mawrin; Cuong Hoang-Vu; Albert Roessner; Hendrik Lehnert
Journal:  J Clin Endocrinol Metab       Date:  2003-09       Impact factor: 5.958

8.  Telomerase activation and expression of its catalytic subunits in benign and malignant tumors of the parathyroid.

Authors:  Naoyoshi Onoda; Kana Ogisawa; Tetsuro Ishikawa; Chiemi Takenaka; Hideki Tahara; Masaaki Inaba; Tsutomu Takashima; Kosei Hirakawa
Journal:  Surg Today       Date:  2004       Impact factor: 2.549

9.  Expression of the human telomerase reverse transcriptase in pheochromocytoma and neuroblastoma tissues.

Authors:  Kazumasa Isobe; Toru Yashiro; Sakie Omura; Michio Kaneko; Setsuko Kaneko; Hiroshi Kamma; Ichiro Tatsuno; Kazuhiro Takekoshi; Yasushi Kawakami; Toshiaki Nakai
Journal:  Endocr J       Date:  2004-02       Impact factor: 2.349

10.  Telomere dysfunction: a potential cancer predisposition factor.

Authors:  Xifeng Wu; Christopher I Amos; Yong Zhu; Hua Zhao; Barton H Grossman; Jerry W Shay; Sherry Luo; Waun Ki Hong; Margaret R Spitz
Journal:  J Natl Cancer Inst       Date:  2003-08-20       Impact factor: 13.506

View more
  5 in total

1.  In silico evaluation of TERT inhibition by anticancer drugs.

Authors:  Porika Mahendar; Kalam Sirisha; Umasankar Kulandaivelu; Prakhya Laxmi Jaya Shankar; Tippani Radhika; Abbagani Sadanandam
Journal:  J Mol Model       Date:  2012-06-06       Impact factor: 1.810

2.  Absence of TERT promoter mutations in pituitary adenomas.

Authors:  C S Martins; M de Castro; R T Calado
Journal:  J Endocrinol Invest       Date:  2016-05-06       Impact factor: 4.256

3.  Telomerase activation in small intestinal neuroendocrine tumours is associated with aberrant TERT promoter methylation, but not hot-spot mutations.

Authors:  Omid Fotouhi; Mehran Ghaderi; Na Wang; Jan Zedenius; Magnus Kjellman; Dawei Xu; C Christofer Juhlin; Catharina Larsson
Journal:  Epigenetics       Date:  2019-07-19       Impact factor: 4.528

4.  GABPA inhibits invasion/metastasis in papillary thyroid carcinoma by regulating DICER1 expression.

Authors:  Xiaotian Yuan; Ninni Mu; Na Wang; Klas Strååt; Anastasios Sofiadis; Yanxia Guo; Adam Stenman; Kailin Li; Guanghui Cheng; Lu Zhang; Feng Kong; Lars Ekblad; Johan Wennerberg; Inga-Lena Nilsson; C Christofer Juhlin; Catharina Larsson; Dawei Xu
Journal:  Oncogene       Date:  2018-09-04       Impact factor: 9.867

Review 5.  Papillary Thyroid Cancer Prognosis: An Evolving Field.

Authors:  Salvatore Ulisse; Enke Baldini; Augusto Lauro; Daniele Pironi; Domenico Tripodi; Eleonora Lori; Iulia Catalina Ferent; Maria Ida Amabile; Antonio Catania; Filippo Maria Di Matteo; Flavio Forte; Alberto Santoro; Piergaspare Palumbo; Vito D'Andrea; Salvatore Sorrenti
Journal:  Cancers (Basel)       Date:  2021-11-07       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.